Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Head and Neck Squamous Cell Carcinoma Clinical Trials

13 recruiting trials for Head and Neck Squamous Cell Carcinoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
13
Total Trials
13
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06999187

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or...

Sponsor: Dren BioEnrolling: 9610 locations
RECRUITINGPhase 2NCT05229614

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

Immunotherapy has become the standard of care in different advanced malignancies. Its effectiveness in the palliative setting was demonstrated by several phase III trials....

Sponsor: CNAO National Center of Oncological HadrontherapyEnrolling: 274 locations
RECRUITINGPhase 1NCT07503808

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in...

Sponsor: IDEAYA BiosciencesEnrolling: 1505 locations
RECRUITINGPhase 2NCT06422403

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab,...

Sponsor: National University Hospital, SingaporeEnrolling: 3601 location
RECRUITINGEarly Phase 1NCT06645808

PET-imaging of Two Vartumabs in Patients With Solid Tumors

VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody...

Sponsor: Var2 PharmaceuticalsEnrolling: 321 location
RECRUITINGPhase 1 / Phase 2NCT07109726

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with...

Sponsor: Terremoto Biosciences Inc.Enrolling: 20515 locations
RECRUITINGPhase 1 / Phase 2NCT06747585

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II...

Sponsor: Alentis Therapeutics AGEnrolling: 17020 locations
RECRUITINGPhase 1NCT06761937

Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients

Patients with head and neck cancer treated with radiotherapy (RT) have a substantial change of recurrence of the tumor in the pharynx or lymph nodes in the neck. Once tumor and/or...

Sponsor: Erasmus Medical CenterEnrolling: 301 location
RECRUITINGPhase 2NCT06725498

Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

This study pioneers a novel approach by integrating a new auxiliary chemo-immunotherapy regimen, which is then followed by an evaluation of the potential for surgical resection....

Sponsor: Beijing Tongren HospitalEnrolling: 501 location
RECRUITINGPhase 1NCT06109207

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

The purpose of this study is to explore the safety and feasibility of anti-programmed cell death protein 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase...

Sponsor: West China HospitalEnrolling: 61 location
RECRUITINGPhase 1 / Phase 2NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or...

Sponsor: VM Oncology, LLCEnrolling: 24215 locations
RECRUITINGPhase 1NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced...

Sponsor: Nurix Therapeutics, Inc.Enrolling: 34517 locations
RECRUITINGPhase 1NCT06444815

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and...

Sponsor: KaliVir ImmunotherapeuticsEnrolling: 607 locations

Frequently Asked Questions

There are currently 13 clinical trials for Head and Neck Squamous Cell Carcinoma, with 13 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Head and Neck Squamous Cell Carcinoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Head and Neck Squamous Cell Carcinoma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

For this entity, the underlying data on this page comes from the NIH ClinicalTrials.gov registry. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.